Management of noninfectious posterior uveitis with intravitreal drug therapy

Hui Yi Tan,1 Aniruddha Agarwal,2 Cecilia S Lee,3 Jay Chhablani,4 Vishali Gupta,5 Manoj Khatri,6 Jayabalan Nirmal,7 Carlos Pavesio,8 Rupesh Agrawal1,7–9 1Yong Loo Lin School of Medicine, National University of Singapore, Singapore; 2Department of Vitreoretina, Stanley M Truhlsen Eye Instit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tan HY, Agarwal A, Lee CS, Chhablani J, Gupta V, Khatri M, Nirmal J, Pavesio C, Agrawal R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Intravitreal therapy Noninfectious uveitis Posterior uveitis Intravitreal steroids Intravitreal methotrexate; Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/1271dd046bf6470ab0beacce9acad7db
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1271dd046bf6470ab0beacce9acad7db
record_format	dspace
spelling	oai:doaj.org-article:1271dd046bf6470ab0beacce9acad7db2021-12-02T02:36:25ZManagement of noninfectious posterior uveitis with intravitreal drug therapy1177-5483https://doaj.org/article/1271dd046bf6470ab0beacce9acad7db2016-10-01T00:00:00Zhttps://www.dovepress.com/management-of-noninfectious-posterior-uveitis-with-intravitreal-drug-t-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Hui Yi Tan,1 Aniruddha Agarwal,2 Cecilia S Lee,3 Jay Chhablani,4 Vishali Gupta,5 Manoj Khatri,6 Jayabalan Nirmal,7 Carlos Pavesio,8 Rupesh Agrawal1,7–9 1Yong Loo Lin School of Medicine, National University of Singapore, Singapore; 2Department of Vitreoretina, Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, 3Department of Ophthalmology, University of Washington, Seattle, WA, USA; 4Department of Vitreoretina, L V Prasad Eye Institute, Hyderabad, Telangana, 5Department of Retina and Uvea, Post Graduate Institute of Medical Education and Research, Chandigarh, 6Department of Retina, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India; 7School of Material Science and Engineering, Nanyang Technological University, Singapore; 8Department of Medical Retina, Moorfields Eye Hospital, NHS Foundation Trust, London, UK; 9Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore Abstract: Uveitis is an important cause of vision loss worldwide due to its sight-threatening complications, especially cystoid macular edema, as well as choroidal neovascularization, macular ischemia, cataract, and glaucoma. Systemic corticosteroids are the mainstay of therapy for noninfectious posterior uveitis; however, various systemic side effects can occur. Intravitreal medication achieves a therapeutic level in the vitreous while minimizing systemic complications and is thus used as an exciting alternative. Corticosteroids, antivascular endothelial growth factors, immunomodulators such as methotrexate and sirolimus, and nonsteroidal anti-inflammatory drugs are currently available for intravitreal therapy. This article reviews the existing literature for efficacy and safety of these various options for intravitreal drug therapy for the management of noninfectious uveitis (mainly intermediate, posterior, and panuveitis). Keywords: intravitreal therapy, noninfectious uveitis, posterior uveitis, intravitreal steroids, intravitreal methotrexateTan HYAgarwal ALee CSChhablani JGupta VKhatri MNirmal JPavesio CAgrawal RDove Medical PressarticleIntravitreal therapyNoninfectious uveitisPosterior uveitisIntravitreal steroidsIntravitreal methotrexate;OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 10, Pp 1983-2020 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Intravitreal therapy Noninfectious uveitis Posterior uveitis Intravitreal steroids Intravitreal methotrexate; Ophthalmology RE1-994
spellingShingle	Intravitreal therapy Noninfectious uveitis Posterior uveitis Intravitreal steroids Intravitreal methotrexate; Ophthalmology RE1-994 Tan HY Agarwal A Lee CS Chhablani J Gupta V Khatri M Nirmal J Pavesio C Agrawal R Management of noninfectious posterior uveitis with intravitreal drug therapy
description	Hui Yi Tan,1 Aniruddha Agarwal,2 Cecilia S Lee,3 Jay Chhablani,4 Vishali Gupta,5 Manoj Khatri,6 Jayabalan Nirmal,7 Carlos Pavesio,8 Rupesh Agrawal1,7–9 1Yong Loo Lin School of Medicine, National University of Singapore, Singapore; 2Department of Vitreoretina, Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, 3Department of Ophthalmology, University of Washington, Seattle, WA, USA; 4Department of Vitreoretina, L V Prasad Eye Institute, Hyderabad, Telangana, 5Department of Retina and Uvea, Post Graduate Institute of Medical Education and Research, Chandigarh, 6Department of Retina, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India; 7School of Material Science and Engineering, Nanyang Technological University, Singapore; 8Department of Medical Retina, Moorfields Eye Hospital, NHS Foundation Trust, London, UK; 9Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore Abstract: Uveitis is an important cause of vision loss worldwide due to its sight-threatening complications, especially cystoid macular edema, as well as choroidal neovascularization, macular ischemia, cataract, and glaucoma. Systemic corticosteroids are the mainstay of therapy for noninfectious posterior uveitis; however, various systemic side effects can occur. Intravitreal medication achieves a therapeutic level in the vitreous while minimizing systemic complications and is thus used as an exciting alternative. Corticosteroids, antivascular endothelial growth factors, immunomodulators such as methotrexate and sirolimus, and nonsteroidal anti-inflammatory drugs are currently available for intravitreal therapy. This article reviews the existing literature for efficacy and safety of these various options for intravitreal drug therapy for the management of noninfectious uveitis (mainly intermediate, posterior, and panuveitis). Keywords: intravitreal therapy, noninfectious uveitis, posterior uveitis, intravitreal steroids, intravitreal methotrexate
format	article
author	Tan HY Agarwal A Lee CS Chhablani J Gupta V Khatri M Nirmal J Pavesio C Agrawal R
author_facet	Tan HY Agarwal A Lee CS Chhablani J Gupta V Khatri M Nirmal J Pavesio C Agrawal R
author_sort	Tan HY
title	Management of noninfectious posterior uveitis with intravitreal drug therapy
title_short	Management of noninfectious posterior uveitis with intravitreal drug therapy
title_full	Management of noninfectious posterior uveitis with intravitreal drug therapy
title_fullStr	Management of noninfectious posterior uveitis with intravitreal drug therapy
title_full_unstemmed	Management of noninfectious posterior uveitis with intravitreal drug therapy
title_sort	management of noninfectious posterior uveitis with intravitreal drug therapy
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/1271dd046bf6470ab0beacce9acad7db
work_keys_str_mv	AT tanhy managementofnoninfectiousposterioruveitiswithintravitrealdrugtherapy AT agarwala managementofnoninfectiousposterioruveitiswithintravitrealdrugtherapy AT leecs managementofnoninfectiousposterioruveitiswithintravitrealdrugtherapy AT chhablanij managementofnoninfectiousposterioruveitiswithintravitrealdrugtherapy AT guptav managementofnoninfectiousposterioruveitiswithintravitrealdrugtherapy AT khatrim managementofnoninfectiousposterioruveitiswithintravitrealdrugtherapy AT nirmalj managementofnoninfectiousposterioruveitiswithintravitrealdrugtherapy AT pavesioc managementofnoninfectiousposterioruveitiswithintravitrealdrugtherapy AT agrawalr managementofnoninfectiousposterioruveitiswithintravitrealdrugtherapy
_version_	1718402329480265728

Management of noninfectious posterior uveitis with intravitreal drug therapy

Ejemplares similares